A new tool from the state of Ohio aims to help officials proactively address heightened drug overdose risk in local ...

The European medicines regulator said on Friday it will review safety information for Eisai and Biogen's Leqembi that the agency recommended for approval in November for some patients with early ...

Paul Howe, chief commercial officer at Protega Pharma, discusses how regulatory agencies are updating their policies based on the presence of abuse-deterrent medications. Pharmaceutical Executive: How ...

The Trump administration’s Centers for Medicare & Medicaid Services (CMS) has signaled that it will be revamping the process ...

Recent cases have highlighted differing legal responses to drug abuse. While some individuals struggling with substance use are sent to rehabilitation, others face prosecution and possible prison ...

Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...

The genetic polymorphisms that may affect individual responses to cardiovascular agents are reviewed, and the application of pharmacogenetics to cardiovascular disease management is discussed.

Two overarching goals tied to a futuristic vision of personalized medicine are to maximize individually derived benefits from available therapeutic drugs or biological agents and identify a ...

Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.

Illinois lawmakers express their support of the Prescription Drug Affordability Act in response to former President Biden’s ...